HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer - Preclinical rationale
Favorite
Share
More Options
15

Open in WPS to view all 15 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
